The approval of a new oral postexposure prophylaxis for COVID-19 marks a significant advancement in the disease's prevention ...
FDA approves ensitrelvir for COVID-19 postexposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms. The FDA recently approved ensitrelvir (Xocova; Shionogi), an ...
The Centers for Disease Control and Prevention (CDC), on behalf of the U.S. Public Health Service (PHS), has released the 2025 Guidelines for the Management of Occupational Exposure to Human ...
The FDA has approved the oral antiviral Xocova (ensitrelvir) for postexposure prophylaxis of COVID-19 in adults and adolescents.
Morning Overview on MSN
The FDA cleared Xocova, the first oral antiviral to prevent COVID-19 after exposure, in a five-day pill course shown to cut infections in a phase 3 trial
Households where someone tests positive for COVID-19 now have an oral drug option to protect the people around them. The FDA ...
Persons initiating nPEP should be informed that preexposure prophylaxis (PrEP) can reduce their risk for acquiring HIV in the case of repeat or continuing exposure after the nPEP course. HealthDay ...
A new commentary published in Annals of Internal Medicine from Roy Gulick, MD, Chief, Division of Infectious Diseases and Professor of Medicine at Weill Cornell Medicine, highlights what's new in the ...
Mary R. Tanner, M.D., from the CDC in Atlanta, and colleagues updated the 2016 nPEP guidelines and considerations for use in the United States, including considerations for testing and nPEP regimens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results